These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 3672571)

  • 1. Changes in lignocaine disposition during long-term infusion in patients with acute ventricular arrhythmias.
    Thomson AH; Kelman AW; de Vane PJ; Hillis WS; Whiting B
    Ther Drug Monit; 1987 Sep; 9(3):283-91. PubMed ID: 3672571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On the role of alpha 1-acid glycoprotein in lignocaine accumulation following myocardial infarction.
    Barchowsky A; Shand DG; Stargel WW; Wagner GS; Routledge PA
    Br J Clin Pharmacol; 1982 Mar; 13(3):411-5. PubMed ID: 7059443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetics of lignocaine and beta-adrenoceptor antagonists in patients with acute myocardial infarction.
    Nattel S; Gagne G; Pineau M
    Clin Pharmacokinet; 1987 Nov; 13(5):293-316. PubMed ID: 2891461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function.
    Orlando R; Piccoli P; De Martin S; Padrini R; Palatini P
    Br J Clin Pharmacol; 2003 Jan; 55(1):86-93. PubMed ID: 12534644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lignocaine and indocyanine green kinetics in patients following myocardial infarction.
    Bax ND; Tucker GT; Woods HF
    Br J Clin Pharmacol; 1980 Oct; 10(4):353-61. PubMed ID: 7448106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics of lignocaine.
    Benowitz NL; Meister W
    Clin Pharmacokinet; 1978; 3(3):177-201. PubMed ID: 350470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lignocaine therapy after acute myocardial infarction.
    Chopra MP; Portal RW; Aber CP
    Br Med J; 1969 Jan; 1(5638):213-6. PubMed ID: 5762622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative trial of mexiletine and lignocaine in the treatment of early ventricular tachyarrhythmias after acute myocardial infarction.
    Horowitz JD; Anavekar SN; Morris PM; Goble AJ; Doyle AE; Louis WJ
    J Cardiovasc Pharmacol; 1981; 3(3):409-19. PubMed ID: 6168823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of dehydration and hyperosmolal hydration on lignocaine and metabolites disposition in conscious rabbits.
    Chamelian M; Lécrivain A; Robichaud A; du Souich P
    Br J Pharmacol; 1994 Sep; 113(1):317-23. PubMed ID: 7812627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. alpha 1-Acid glycoprotein and plasma lidocaine binding.
    Shand DG
    Clin Pharmacokinet; 1984 Jan; 9 Suppl 1():27-31. PubMed ID: 6705424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of age and smoking on the plasma protein binding of lignocaine and diazepam.
    Davis D; Grossman SH; Kitchell BB; Shand DG; Routledge PA
    Br J Clin Pharmacol; 1985 Feb; 19(2):261-5. PubMed ID: 3986083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of individual dosage requirements for lignocaine: a validation study for Bayesian forecasting in Japanese patients.
    Uematsu T; Hirayama H; Nagashima S; Yamazaki T; Tsuchiya N; Sato R; Nakashima M
    Ther Drug Monit; 1989; 11(1):25-31. PubMed ID: 2911849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between alpha 1-acid glycoprotein and lidocaine disposition in myocardial infarction.
    Routledge PA; Shand DG; Barchowsky A; Wagner G; Stargel WW
    Clin Pharmacol Ther; 1981 Aug; 30(2):154-7. PubMed ID: 7249498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid estimation of unbound lidocaine clearance in cardiac patients: implications for reducing toxicity.
    Denson DD; Toltzis RJ; Ernst TF; Youngs CH; Thomas RL; Grummich KW
    J Clin Pharmacol; 1988 Nov; 28(11):995-1000. PubMed ID: 3243921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerability and antiarrhythmic efficacy of disopyramide compared to lignocaine in selected patients with suspected acute myocardial infarction.
    Rønnevik PK; Gundersen T; Abrahamsen AM
    Eur Heart J; 1987 Jan; 8(1):19-24. PubMed ID: 2880718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors affecting free (unbound) lignocaine concentration in suspected acute myocardial infarction.
    Routledge PA; Stargel WW; Barchowsky A; Wagner GS; Shand DG
    Br J Clin Pharmacol; 1989 Nov; 28(5):593-7. PubMed ID: 2590613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Logical approach to lignocaine therapy.
    Aps C; Bell JA; Jenkins BS; Poole-Wilson PA; Reynolds F
    Br Med J; 1976 Jan; 1(6000):13-5. PubMed ID: 1247716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A free lignocaine index as a guide to unbound drug concentration.
    Routledge PA; Lazar JD; Barchowsky A; Stargel WW; Wagner GS; Shand DG
    Br J Clin Pharmacol; 1985 Dec; 20(6):695-8. PubMed ID: 4092000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Observations on intravenous administration of lignocaine in patients with myocardial infarction.
    Campbell NP; Kelly JG; Adgey AA; McDevitt DG; Pantridge JF
    Br Heart J; 1978 Dec; 40(12):1371-5. PubMed ID: 737094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lignocaine therapy for ventricular ectopic activity after acute myocardial infarction: a double-blind trial.
    Chopra MP; Thadani U; Portal RW; Aber CP
    Br Med J; 1971 Sep; 3(5776):668-70. PubMed ID: 4936439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.